Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Healthy Yuan (600380.SH): Clarithromycin tablets pass the consistency evaluation of generic drugs
Published Time：
2022-03-15
According to the Zhitong Finance APP, HealthGen (600380.SH) announced that its subsidiary, Lizhu Pharmaceutical Group Co., Ltd. (“Lizhu Group”), recently received an approval document from the National Medical Products Administration for its subsidiary Lizhu Pharmaceutical Factory’s clarithromycin tablets, confirming that the product has passed the consistency evaluation of quality and efficacy for generic drugs.
It is understood that clarithromycin tablets are a Class B drug in the "National Catalogue of Essential Medicines for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance" (Medical Insurance [2021] No. 50), suitable for treating infections caused by clarithromycin-sensitive pathogens, including: 1. Lower respiratory tract infections; 2. Upper respiratory tract infections; 3. Skin and soft tissue infections; 4. Localized or disseminated infections; 5. Mixed infections; 6. Eradication of Helicobacter pylori; 7. Odontogenic infections.
Source: Tencent Self-Selected Stocks
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.